Global executive search and interim management specialist, Horton International UK, is delighted to announce the appointment of Emma Whittle as Partner within its Global Healthcare arm.
Emma brings to the team over 20 years’ experience within search and talent acquisition, built across a range of industries and with significant emphasis on hiring for the life sciences sectors, including technology digitalisation, medical technology and diagnostics.
Commenting on her appointment, Emma said: “This is an incredibly important time to be supporting the life sciences arena. R&D activity has…
A biotech start-up, whose technology aims to tackle cornea
donor tissue shortages and speed up life-changing transplants worldwide, has moved into a specialist lab facility – The Biosphere on Newcastle Helix.
3D Bio-Tissues and their technology is the outcome of more than 20 years of pioneering research. They specialise in creating ‘bio-equivalent’ structural tissues. Their technology works by applying novel bio-inspired manufacturing processes to generate complex structures. The team’s goal is to create structured, functional, and scalable tissues for both clinical and industrial use.…
Cambridge 26th November 2020: The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups - ArkVax, Paediatric HealthTech, ConcR and Stroma Biosciences - went head-to-head on Wednesday afternoon (Nov 25th); competing for £10,000 additional funding generously donated by CMS Ventures in the Accelerate@Babraham with AstraZeneca: Start-up Pitching Competition.
The pitching competition formed part of AstraZeneca’s annual ‘Cambridge Exchange’ event, during which EVP of Biopharmaceutical R&D Sir Mene Pangalos and key figures from the Universities of Cambridge and…
o2h ventures is delighted to announce the launch of their HMRC approved knowledge intensive EIS fund, focussing on supporting the expansion of UK research and development in biotech therapeutics and AI.
To support the Government’s aim to strengthen and grow UK innovation, which were known to be capital and research intensive, the EIS knowledge intensive fund has been launched to pledge support to companies working in this space, providing them access to capital to develop their early novel ideas.
Knowledge intensive investing offers investors an opportunity to take advantage of the…
AMSBIO offer a wide range of Heparan Sufate antibodies, enzymes, standards and ready-to-use Heparanase activity assays for researchers seeking to better understand COVID-19 and thereby to combat the pandemic.Heparan Sulfate (HS) is increasingly recognised as a key factor in infection by the SARS-CoV-2 virus, which is the cause of the current COVID-19 Coronavirus pandemic. Using HS antibodies from AMSBIO, researchers have demonstrated that Heparanase enzyme contributes to the pathogenesis of COVID-19, with both Heparanase activity and HS levels being elevated in plasma of Covid-19 patients. In…
SOMERSET, N.J. – November 23, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
This agreement will…
CAMBRIDGE UK, 16 November 2020:
Start Codon, a life science and healthcare business accelerator based in Cambridge, UK, today announced that it has closed Start Codon Fund I LP (the “Fund”) at £15 million. The Fund will be used to support Start Codon’s offering to start-ups, which includes a minimum of £250K seed funding, business support services, expert guidance, and access to cutting-edge office and lab facilities. Limited Partner ("LP") investors in the Fund include Novartis International AG and Cambridge Innovation Capital.
In addition to their investment in the Fund, Novartis will work…
Decentralised model to allow remote participation in trial among patients
Trial design adapted to further investigate potential link between COVID-19 and hypertension
London, UK, 18 November 2020: Closed Loop Medicine (‘CLM’) a clinical stage therapeutics company developing drug + digital combination products, announces that the first patient has been recruited into its pivotal clinical trial investigating CLM’s integrated precision care solution for patients with hypertension.
The clinical trial, called Personal COVID BP, will see up to 1,000 patients recruited for a study…
ARU's annual magazine Research and Innovation Highlights 2020 magazine is now live.
Stories from across ARU, shining a spotlight on our world-leading and impactful research, as well as case studies that explore how we're working with industry to support economic growth, nurturing our talented students into experienced graduates of the future and improving the skillset of the community from as close to home as Essex to as far away as India.
There's also a special feature on COVID19 research and how we're making a difference during the pandemic. All our news stories can be…